OptiBiotix Health plc
("OptiBiotix" or the "Company")
Manufacturing, supply and profit sharing agreement with Morley Foods
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol,
diabetes and skin care, announces it has entered into a manufacturing and supply agreement with John Morley Foods, ("Morleys"). The agreement grants Morleys an exclusive licence to manufacture and supply the SlimBiome® weight management technology in muesli packs within the UK, in return for 50% of the profit.
Morleys is a private company and a leading supplier of high quality ingredients to breakfast cereal and food manufacturers including major retailers and many global consumer food brands. Morleys have invested substantive resource over the last six months in developing a range of muesli products containing SlimBiome® to be sold as own label products to major retailer or as product line extensions to existing well- known brands.
SlimBiome®, a patented combination of natural ingredients developed by experts to provide hunger free weight loss, recently won the award for Weight Management of the Year at Vitafoods European trade show. Morleys will use their best endeavours to promote and expand the supply of SlimBiome® in muesli packs, bringing it to the attention of major retailers and branded cereal manufactures within the United Kingdom. The development of muesli breakfast products allows OptiBiotix to extend its GoFigure™ range of online products and create 'health and wellbeing' own label brands for supermarkets within the UK.
This agreement, with one of the UK's leading ingredient suppliers, is another step in expanding the range of products containing SlimBiome® to meet the needs of major UK retailers and the Iarge consumer markets of India and the USA.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply and profit sharing agreement with Morleys. We chose Morleys due to their reputation as one of the UK's leading suppliers of specialist ingredients and the energy and passion they have shown in developing a wide range of muesli products containing SlimBiome® over the last six months. We believe working with Morleys, and similar partners around the world, provides the best opportunity of meeting the requirements of major retailers and global brands who are looking to develop healthy products to meet growing consumer demand."
Simon Brown, Managing Director of John Morley Group added: "This is an exciting development, and a range like this has not been done by anyone else. Mueslis are healthy, but now we're creating a muesli-plus, something that will help people control mid-morning snacking urges by making them feel fuller for longer. Not only that but SlimBiome®, as a prebiotic, is good for healthy gut bacteria. Our plan is to launch single serving muesli pots as well as the standard bagged format to target the individual market. We are delighted to be working with OptiBiotix and taking our relationship forward in new and exciting ways."
OptiBiotix Health plc |
www.optibiotix.com |
Stephen O'Hara, Chief Executive |
Contact via Walbrook below |
|
|
Cairn Financial Advisers LLP (NOMAD) |
Tel: 020 7213 0883 |
Liam Murray / Jo Turner |
|
FinnCap (Broker) |
Tel: 020 7220 0500 |
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance) |
|
Abigail Wayne (Corporate Broking) |
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or [email protected] |
Anna Dunphy |
Mob: 07876 741 001 |
| |
|
|
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
About Morley Foods www.johnmorley.co.uk
